Our in vitro success counsel that EAM-2201 need to be examined with regards to opportunity in vivo pharmacokinetic drug–drug interactions caused by time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 actions and aggressive inhibition of UGT1A3 exercise. This is a preview of membership content, log in by using an institution https://chiefx728hxl0.mycoolwiki.com/user